EUCTR2018-000450-21-FRActive, not recruitingPhase 1
Prospective, Randomized, Open, Controlled, Multicenter Study to Evaluate the Safety and Efficacy of the MON4STRAT Approach for Optimizing Meropenem Therapy in Intubated and Mechanically-Ventilated, Adult Patients with severe Gram-Negative lower respiratory tract infection - MON4STRAT
FUNDACIÓN PARA INVESTIGACIÓN BIOMÉDICA DEL HOSPITAL UNIVERSITARIO RAMÓN Y CAJA0 sites150 target enrollmentStarted: August 24, 2018Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 150
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
Inclusion Criteria
- •1.Males and non-pregnant, non-lactating females, 18 years of age or older;
- •2.Currently intubated and mechanically-ventilated subjects in the ICU;
- •3.a. Suspicion of Lower Respiratory Tract infection defined as at least two of the following:
- •fever, defined as a tympanic/ rectal/core temperature >38,3°C , or hypothermia, defined as a rectal/core body temperature of <35,0°C;
- •leukocyte count >10,000/mm3 or <4,500/mm3, or an immature neutrophil (band) count >15% regardless of the peripheral leukocyte count;
- •new onset of purulent sputum or respiratory secretions, or a change in the character of sputum;
- •a new or progressive pulmonary infiltrate on chest X-rays.(criterion only applicable for Spain and Belgium)
- •b. A new or progressive pulmonary infiltrate on chest X-rays. (only for France).
- •As indicated in section 2.4, in France, only patients fullfilling all the criteria for nosocomial pneumonia will be included.
- •4.Presence of Gram-negative organism(s) by Gram stain OR by culture of pre-therapy respiratory specimen (eg, endotracheal aspirate [ETA], bronchoalveolar lavage [BAL], or mini-BAL) OR previous colonization 48 hours before screening;
- •5.Initial empiric antimicrobial regimen combining meropenem with an aminoglycoside or a fluoroquinolone active on Pseudomonas, plus MRSA coverage when indicated, in accordance with the 2016 ATS/IDSA guidelines for HAP/VAP/HCAP;
- •6.At least two of the risk factors described as associated with HAP/VAP caused by multidrug-resistant organisms in the guidelines of the ATS/IDSA for HAP/VAP (Clin Infect Dis. 2016 Sep 1;63(5):e61-e111) and those of the ESICM/ECCMID societies (Eur Respir J. 2017 Sep 10;50(3):
- •Antimicrobial therapy in the preceding two weeks;
- •Current hospitalization =5 days;
- •High frequency (>10%) of antibiotic resistance in the community or in the specific hospital unit, depending in particular on data issued from local official committees in line with the national epidemiological surveillance program; ;
- •Immunosuppressive disease and/or therapy;
- •Residence in a nursing home or extended care facility.
- •7.Clinical pulmonary infection score (CPIS) =6;
- •8.Expected to remain intubated and mechanically ventilated for =72 hours based on investigator estimate;
- •9.Expected to participate in the study through 28 days post first dose of meropenem;
- •10.Provision of written informed consent by the subject or subject’s, family member or a closerelative.
- •[A waiver of consent will be asked to each Ethical Committee allowing for randomizing patients when he/she is unable to give consent and no, family member or a close relative can be contacted, in accordance with law specifications of emergency consent. In that case, family member or close relative or patients will be asked to give his/her consent for continuation of the trial when his/her condition permits];
- •11. Affiliation to a social security system (recipient or assign)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age
Exclusion Criteria
- •Subjects who have received antibiotic therapy for Gram-negative LRT infection for = 36 hours at the time of randomization;
- •2.Hypersensitivity to meropenem, Hypersensitivity to any other carbapenem antibacterial agent, Severe hypersentivity (eg anaphylactic reaction, severe skin reaction) to any other type of beta-lactam antibacterial agent (e.g.penicillins or cephalosporins)
- •3.Subjects taking valproic/acid sodium valproat/valpromide for a seizure disorder (other anticonvulsivants are allowed)
- •4.Subjects who have had a left hemisphere stroke (right hemisphere affected is allowed) within five days and there is an increased risk of fatal brain oedema as indicated by a major early computerized tomography hypodensity exceeding 50% of the middle cerebral artery territory, and/or involvement of additional vascular territories;
- •5.Subjects who have cystic fibrosis, human immunodeficiency virus (HIV) infection with CD4 count <100 cell/mm3 (HIV testing is not required as part of this protocol), or invasive fungal infection of the lung;
- •6.Neutropenia (screening absolute neutrophil count <103 neutrophils/mm3);
- •7. Bone marrow transplant;
- •8.Subjects who have primary lung cancer with known endobronchial obstruction (post-operative patients after lung cancer resection are eligible for the study);
- •9-.Subjects with another focus of infection requiring concurrent antibiotics that would interfere with evaluation of the response to study treatment;
- •10 Subjects for whom therapy will require aerosolized antibiotics;
- •11. Subjects for whom therapy will require intermittent hemodialysis (patients treated with continuous renal replacement techniques are eligible for the study);
- •12. Burns greater than 40% of total body surface area;
- •13. Subjects with intractable septic shock (subjects requiring ongoing treatment with vasopressors will be eligible for the study if their hypotension is controlled and acidosis has resolved);
- •14. Rapidly fatal illness with death likely within the next 72 hours;
- •15. Subjects who have been on mechanical ventilation for >28 days;
- •16. Subjects who were previously enrolled in this study;
- •17. Subjects under curatorship or tutorship.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Study to Evaluate the Safety and Efficacy of the MON4STRAT Approach for Optimizing Meropenem Therapy in Intubated and Mechanically-Ventilated, Adult Patients with Gram-Negative Lower Respiratory Tract Infection Including Nosocomial Pneumonia and Severe TracheobronchitisEUCTR2018-000450-21-ESFundación Investigación Biomédica Hospital Ramón y Cajal50
Active, not recruiting
Not Applicable
Open, Prospective, Controlled, Randomised, Multicenter Phase II Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Moist Wound Healing Dressing alone in Accelerating the Epithelialization of Split Thickness Skin Graft Donor SitesOleoSplit-Trial - OleoSplit-TrialEs handelt sich um eine offene, prospektive, kontrollierte, randomisierte, multizentrische Studie der Phase II, die eine intra-individuelle Wirksamkeit und Verträglichkeit des Oleogel-S10 mit einer feuchten Wundauflage im Hinblick auf einen Beschleunigung der Epithelialisierung der Wunde nach der Entnahme von Spalthaut mit einander vergleicht.EUCTR2009-017418-56-DEBirken GmbH80
Recruiting
Phase 3
Maternal oxygen therapy during pregnancy for unborn babies with underdeveloped structures on the left side of the heart2024-512679-11-00Universitaetsklinikum Erlangen AöR64
Recruiting
Phase 1
Maternal oxygen therapy during pregnancy for unborn babies with underdeveloped structures on the left side of the heartunborn baby with developmental disorder of the left side of the heartMedDRA version: 20.0Level: PTClassification code: 10021076Term: Hypoplastic left heart syndrome Class: 100000004850CTIS2024-512679-11-00niversitaetsklinikum Erlangen AöR64
Active, not recruiting
Not Applicable
Open, randomized, prospective, controlled, multicentre study to evaluate the efficacy and safety of multiple intraportal applications of liver cell suspension in patients with acute liver failure not eligible for orthotopic liver transplantatioAcute Liver FailureSubgroups of patients with indications falling under ICD classification codes:K70.4, K71, K72, K75, K76, K77MedDRA version: 9.1Level: LLTClassification code 10049844Term: Acute liver failureEUCTR2005-000837-39-DECytonet GmbH & Co. KG90